Wednesday, May 23, 2012

Phase 3 data on Insulin Degludec and degludec plus in Japanese patients at 55th Annual Meeting of the Japan Diabetes Society

Sub-analysis of Japanese patients - Phase 3 studies (IDeg) versus insulin-detemir (Levemir)Insulin Degludec when compared with the administration once or twice daily insulin detemir in Japanese Patients, HbA1c improvement was similar in the two groups , while fasting blood glucose level and incidence of nocturnal hypoglycemia was significantly lower. Incidence of nocturnal hypoglycemia were reduced by 52% in the Insulin Degludec group compared to Insulin Detemir.



Sub-analysis of Japanese patients - Phase 3 studies comparing Insulin degludec plus (Insulin Degludec + Insulin Aspart) versus insulin aspartDegludec plus is a blend of 70% Insulin Degludec (basal insulin) with 30% Insulin Aspart (rapid acting insulin). IDegAsp has the feature to maintain the formation of a multi-hexamers of IDeg, does not inhibit the rapid hypoglycemic action of IAsp while maintaining the duration.
Twice daily Degludec plus was  compared twice-daily administration of insulin aspart 30 (BIAsp30) in Japanese patients with type 2 diabetes. HbA1c reduction  with degludec plus was 1.40% as compared to 1.29% in Insulin Aspart.  

 The overall incidence of hypoglycemia was not significantly different, however the frequency of nighttime hypoglycemia was significantly lower in the degludec plus group by  56%  The overall incidence of adverse events was similar in both groups.


Insulin Degludec versus Insulin Glargine 

IDeg, when compared with once-daily administration of IGlar in Japanese  patients, fasting blood glucose and HbA1c in both groups was improved about the same . Overall incidence of hypoglycemia was lower by  13%  in degludec arm while incidence of nocturnal hypoglycemia was lower by 50% in the degludec arm